Advertisement
Advertisement

MBRX

MBRX logo

Moleculin Biotech Inc

1.90
USD
+0.04
+2.15%
Dec 18, 15:59 UTC -5
Closed
...

Moleculin Biotech Inc Profile

About

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin Biotech, Inc. is based in Houston, TX.

Info & Links

CEO

Walter V. Klemp

Headquarters

5300 MEMORIAL DRIVE, SUITE 950
HOUSTON, TX 77007, UNITED STATES

Industry

Pharmaceuticals Major

Sector

Health Technology

Website

www.moleculin.com

Auditor

GRANT THORNTON LLP

Share holders

138

Employees

18

Moleculin Biotech Inc Statistics

Valuation Measures

Market Capitalization2

5.70M

Enterprise Value

-3.71M

Enterprise Value/EBITDA(ttm)

0.13

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

0.88

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-157.44%

Return on Invested Capital(ttm)

-228.43%

Return on Assets(ttm)

-97.16%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-28.79M

Net Income Available to Common(ttm)

-30.15M

Diluted EPS(ttm)

--

Share Statistics

Beta (5Y Monthly)

1.87

52-Week Change

-78.63%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

3.00M

Dividend Yield

0.00%

Float4

2.79M

% Held by Insiders

7.10%

% Held by Institutions

15.52%

Balance Sheet

Total Cash(mrq)

9.40M

Total Cash Per Share(mrq)

3.13

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

2.08%

Quick Ratio(mrq)

2.08%

Book Value Per Share(mrq)

2.49

Cash Flow

Operating Cash Flow Per Share(ytd)

-5.06

Free Cash Flow(ytd)

-18.79M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement